Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:

Therapeutic Areas/Disease States:

Non-Small Cell Lung Cancer (adenocarcinoma)

Intended Audience: Oncologists, Community HCPs; Oncology APP, Patients/Caregivers

Bayer TA Rationale for Educational Support:

Areas of interest based on referenced literature:

Activating HER2mut Alterations as Actionable Biomarkers in NSCLC 

• HER2 in NSCLC: Understanding Alterations and Testing
  • Tissue and ctDNA “liquid biopsy”
  • Interpreting biomarker testing results encompassing HER2-activating mutations
  • Patient education on HER2 testing and treatment goals
• Evolving Treatment Options for NSCLC with HER2-activating mutations
  • Differences between evolving treatment options for NSCLC with HER2-activating mutations
  • Personalizing care plans for patients with NSCLC and HER2-activating mutations
  • Optimizing patient experience
• Empowering Patients Receiving Treatment for HER2-mutated NSCLC 
   
  • Practical solutions to facilitate communication between patients and the care team
  • Help patients and HCPs navigate barriers to care continuity
     
• Monitoring for and managing treatment-related toxicities
   
  • Supportive care strategies and adherence counseling

Proposal Requirements:

All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:

• Needs assessment
• Educational design and rationale for selection (where applicable)
• Learning objectives
• Proposed faculty
• Participant recruitment plan (where applicable)
• Outcomes strategy/plan (required on a quarterly basis)
• Detailed budget 

Provider Justification:

• Copy of most recent accreditation letter and status
• Sample of other program(s) in similar therapeutic areas

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs
• Share activity data and outcomes metrics within 30 days of their availability

References

• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 8.2026 [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2026 [cited 2026 Oct 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
• Wheatley-Price P, Ismaila N, Calles Blanco A, Cetnar J, Conneran T, Desai PA, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2026.3.3. J Clin Oncol. 2026 Aug 17:JCO2601958. doi:10.1200/JCO-26-01958. PMID: 42607282.
• US Food and Drug Administration. FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer [Internet]. Silver Spring (MD): US Food and Drug Administration; 2026 Sep 9 [cited 2026 Oct 11]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-non-squamous-non-small-cell-lung-cancer
• Bayer HealthCare Pharmaceuticals Inc. HYRNUO (sevabertinib) tablets, for oral use: US prescribing information [Internet]. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2026 Sep [cited 2026 Oct 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219972s001lbl.pdf
• Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, et al. Sevabertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;393(18):1819-1832. doi:10.1056/NEJMoa2511065. PMID: 41104928.
• Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, et al. Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer. Cancer Discov. 2026;16(1):81-94. doi:10.1158/2159-8290.CD-25-0605. PMID: 41090369. 
• Loong HH, Le X, Tan DSW, Grassi P, Brega N, Barrientos M, et al. Sevabertinib in patients with advanced HER2-mutant non-small cell lung cancer: expanded data from cohorts D and F of the phase 1/2 SOHO-01 study. Abstract 8622 presented at: American Society of Clinical Oncology Annual Meeting; 2026 May 29-Jun 2; Chicago, IL.
• Le X, Loong HH, Tan DSW, Lin L, Brase JC, Bao W, et al. Molecular landscape of acquired resistance to sevabertinib in HER2-mutant non-small cell lung cancer: results from SOHO-01. Abstract MO12.04 presented at: IASLC 2026 World Conference on Lung Cancer; 2026 Sep 12-15; Seoul, Republic of Korea. Available from: https://wclc.iaslc.org/
• Girard N, Kim TM, Loong HHF, et al. Characterization and management of sevabertinib-induced diarrhea in patients with HER2-mutant advanced non-small cell lung cancer from the phase I/II SOHO-01 study. ESMO Open. 2026;11 Suppl 3:106325. Abstract 18P. doi:10.1016/j.esmoop.2026.106325.
• Bayer. A study to learn more about how well BAY 2927088 works and how safe it is compared with standard treatment in participants who have advanced non-small cell lung cancer with mutations of human epidermal growth factor receptor 2 (HER2): SOHO-02. ClinicalTrials.gov identifier: NCT06452277 [Internet]. Bethesda (MD): National Library of Medicine; 2024 [cited 2026 Oct 11]. Available from: https://clinicaltrials.gov/study/NCT06452277
• Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, et al. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol. 2024;8(1):217. doi:10.1038/s41698-024-00720-9. 
• Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022;7(1):100395. doi:10.1016/j.esmoop.2022.100395.
• Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. doi:10.1016/j.jmoldx.2016.10.002. PMID: 27993330.
• Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;392(23):2321-2333. doi:10.1056/NEJMoa2503704.
• Heymach JV, Yamamoto N, Girard N, Ruiter G, Smit EF, Planchard D, et al. First-line zongertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med. 2026;394(17):1675-1684. doi:10.1056/NEJMoa2516969. PMID: 41985129. 
• Rotow J, et al. Primary results of DESTINY-Lung04: trastuzumab deruxtecan versus standard of care in patients with previously untreated locally advanced or metastatic HER2 (ERBB2)-mutant non-small cell lung cancer. Abstract PL03.08 presented at: IASLC 2026 World Conference on Lung Cancer; 2026 Sep 12-15; Seoul, Republic of Korea. Available from: https://wclc.iaslc.org/
• Jänne PA, Goto Y, Kubo T, Ninomiya K, Kim S-W, Planchard D, et al. Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02- A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC. Journal of Thoracic Oncology. 2025;20(12):1814–28. DOI: 10.1016/j.jtho.2025.07.129.
• Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386(3):241-251. doi:10.1056/NEJMoa2112431. PMID: 34534430. 
• Belcher SM, Mackler E, Muluneh B, Ginex PK, Anderson MK, Bettencourt E, et al. ONS Guidelines to support patient adherence to oral anticancer medications. Oncol Nurs Forum. 2022;49(4):279-295. doi:10.1188/22.ONF.279-295. PMID: 35788731. 
• Pichler T, Mumm F, Dehar N, Dickman E, Díez de Los Ríos de la Serna C, Dinkel A, Heinrich K, Hennink M, Parviainen AD, Raske V, Wicki N, Moore AC. Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: A scoping review. Cancer Med. 2024 Feb;13(3):e6913. doi: 10.1002/cam4.6913. Epub 2024 Jan 31. PMID: 38298115; PMCID: PMC10905543. 
• Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926. doi:10.1200/JCO.2004.04.132. PMID: 15254061. 
• Neuss MN, Gilmore TR, Belderson KM, Billett AL, Conti-Kalchik T, Harvey BE, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. Oncol Nurs Forum. 2017;44(1):31-43. doi:10.1188/17.ONF.31-43.
• American Cancer Society. Targeted drug therapy for non-small cell lung cancer [Internet]. Atlanta (GA): American Cancer Society; [cited 2026 Oct 11]. Available from: https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html